home / stock / aimt / aimt news


AIMT News and Press, Aimmune Therapeutics Inc. From 09/14/20

Stock Information

Company Name: Aimmune Therapeutics Inc.
Stock Symbol: AIMT
Market: NASDAQ
Website: aimmune.com

Menu

AIMT AIMT Quote AIMT Short AIMT News AIMT Articles AIMT Message Board
Get AIMT Alerts

News, Short Squeeze, Breakout and More Instantly...

AIMT - Merger Arbitrage Analysis And Spread Performance - September 13, 2020

This weekly column explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading pos...

AIMT - Nestle initiates tender offer for Aimmune Therapeutics

Nestle ( OTCPK:NSRGY ) subsidiary Société des Produits Nestlé S.A. (SPN) is commencing today a cash tender offer to purchase all of the outstanding common shares of Aimmune Therapeutics (NASDAQ: AIMT ) for $34.50/share. More news on: Nestlé S.A., Aimmune Ther...

AIMT - Nestlé commences tender offer for Aimmune Therapeutics, Inc.

VEVEY, Switzerland , Sept. 14, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. ("Purchaser"), is commencing today a cash tender offer to purchase all of the outstanding shares of common s...

AIMT - ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - AIMT, AKCA, PTI

NEW YORK, NY / ACCESSWIRE / September 12, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its...

AIMT - Aimmune Therapeutics: A Bargain For A Potential Blockbuster Therapy

Investment Thesis Earlier this year, Aimmune Therapeutics, Inc. ( AIMT ) unveiled Palforzia, the first and only FDA approved therapy to suppress the effects of peanut allergy. The lockdown measures hindered its market launch, and the company failed to realize sales to arrest the stock&#...

AIMT - Why Aimmune Therapeutics Stock Jumped by 159% in August

Shares of the peanut allergy drugmaker Aimmune Therapeutics (NASDAQ: AIMT) jumped by a jaw-dropping 159% during August, according to data provided by S&P Global Market Intelligence . The biopharma's shares took flight last month after the announcement of a $2.6 billion merger agreement...

AIMT - SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - MNTA, BMCH, RST, AIMT

NEW YORK, NY / ACCESSWIRE / September 5, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating...

AIMT - Wall Street Breakfast: The Week Ahead

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Stocks avoided back-to-back blowout losses Friday but couldn't quite close out the week with a gain, as a late-afternoon rally fell shor...

AIMT - 2 Mid-Cap Healthcare Stocks to Buy Now

A recent buyout offer for Aimmune (NASDAQ: AIMT) from its deep-pocketed collaboration partner, Nestle (OTC: NSRGY) , drove the biotech stock around 172% higher overnight. As is usually the case following one of these lucrative cash deals, lots of investors have started searching the healt...

AIMT - Moore Kuehn Encourages MNTA, AIMT, ONDK, and OTEL Investors to Contact Law Firm

NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may ultimately s...

Previous 10 Next 10